Longboard Pharmaceuticals, Inc. ((LBPH)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Longboard Pharmaceuticals, Inc. is conducting a pivotal Phase 3 study titled ‘A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Efficacy, Safety, and Tolerability of LP352 in the Treatment of Seizures in Children and Adults With Developmental and Epileptic Encephalopathies.’ The study aims to evaluate the effectiveness and safety of LP352, a promising treatment for seizures associated with developmental and epileptic encephalopathies (DEE), a group of severe neurological disorders.
The intervention being tested is LP352, an experimental drug administered orally or through a G-tube/PEG tube. It is designed to manage seizures in patients with DEE, offering a potential new therapeutic option for this challenging condition.
This interventional study employs a randomized, parallel assignment model with quadruple masking (blinding of participants, care providers, investigators, and outcomes assessors). The primary goal is treatment, ensuring a robust evaluation of LP352’s efficacy and safety compared to a placebo.
The study began on November 11, 2024, with a primary completion date projected for November 2026. The latest update was submitted on July 8, 2025. These timelines are crucial for tracking the study’s progress and anticipating when results might influence market dynamics.
The ongoing study could significantly impact Longboard Pharmaceuticals’ stock performance, especially if LP352 proves effective. Positive outcomes may boost investor confidence and position the company as a leader in the DEE treatment market, potentially affecting competitors in the neurological disorder space.
The study is currently recruiting, with further details available on the ClinicalTrials portal.